Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Purpose
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
Condition
- Allergic Reactions
Eligibility
- Eligible Ages
- Over 4 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Is a patient 4 years old or greater, inclusive, who are scheduled to undergo OFC, AIT, or other relevant allergy challenge. - Has body weight 15 kg or greater at the time of allergy challenge. - Is willing and able to provide written informed consent prior to participating in the study. In the case of minors (<18 years old), assent can be obtained from his/her legal representative, and as much possible from the patient himself/herself. - Patient experiences an allergic reaction that, in the opinion of the Investigator, requires treatment with epinephrine via neffy or IM Adrenalin.
Exclusion Criteria
- Has any clinically significant medical condition that precludes treatment with epinephrine as assessed by the Investigator.
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Neffy |
|
|
|
Active Comparator IM adrenaline |
|
Recruiting Locations
Children's National and nearby locations
Children's National Hospital
Washington D.C., District of Columbia 20010
Washington D.C., District of Columbia 20010
More Details
- NCT ID
- NCT06834165
- Status
- Recruiting
- Sponsor
- ARS Pharmaceuticals, Inc.